Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06388083 · ClinicalTrials.gov registry record · Phase 2
A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease
A Phase 2 study of Stargardt Disease 1 and STGD1, sponsored by Belite Bio.
- Active
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 18
- Study locations
NCT06388083: Active Phase 2 study of Stargardt Disease 1 and STGD1, sponsored by Belite Bio.
NCT06388083 is a Phase 2 study of Stargardt Disease 1 and STGD1 that is active but no longer recruiting, run by Belite Bio. The registered enrollment target is 60 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower). The trial reports 18 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06388083, a Phase 2 study of Stargardt Disease 1 and STGD1, is active but no longer recruiting, sponsored by Belite Bio.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 18
- Study locations
Study Summary
The goal of this clinical trial is to evaluate the safety, tolerability, and efficacy of tinlarebant in subjects with Stargardt Disease
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tinlarebant
Study Locations (18)
Other
- Belite Study Site - Kobe
- Belite Study Site - Kyoto
- Belite Study Site - Tokyo
- UK01 Belite Study Site - London
Texas
- Belite Study Site - US13 - Austin
- Belite Study Site - US03 - Dallas
- Belite Study Site - US12 - The Woodlands
California
- Belite Study Site - US05 - La Jolla
- Belite Study Site - US09 - San Francisco
Minnesota
- Belite Study Site - US11 - Edina
- Belite Study Site - US04 - Rochester
New York
- Belite Study Site - US14 - New York
- Belite Study Site - US10 - Westbury
Arizona
- Belite Study Site - US08 - Phoenix
Florida
- Belite Study Site - US06 - Miami
Massachusetts
- Belite Study Site - US01 - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2024-07-31 |
| Est. Completion | 2028-02 |
| Phase | Phase 2 |
What the registry record for NCT06388083 still lists
NCT06388083 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower).
The record links to 2 conditions, with Stargardt Disease 1 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06388083 lists 18 locations in 10 states (Other, Texas, California).
Frequently Asked Questions
What is clinical trial NCT06388083 about?
NCT06388083 is a clinical study titled "A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease". The goal of this clinical trial is to evaluate the safety, tolerability, and efficacy of tinlarebant in subjects with Stargardt Disease
What is the current status of trial NCT06388083?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2024-07-31. Estimated completion is 2028-02.
What conditions does trial NCT06388083 study?
This clinical trial studies the following conditions: Stargardt Disease 1, STGD1.
What interventions are being tested in trial NCT06388083?
The interventions under investigation include: Placebo (DRUG), Tinlarebant (DRUG).
Who is sponsoring clinical trial NCT06388083?
This trial is sponsored by Belite Bio, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06388083 being conducted?
This trial has 18 study locations across Arizona, California, Florida, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stargardt Disease 1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06388083's enrollment target sits among peer trials
60 1027th of 2000 higher than 868 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI